| Explore the latest insights and content on assay targets relevant to key therapeutic and research areas, including inflammation, oncology, and neuroscience. |
| Explore new assays |
|
|
 |
Targeted protein degradation for neurodegenerative diseases |
|
| Discover how targeted protein degradation (TPD) is advancing as a novel therapeutic strategy for neurodegenerative diseases and explore groundbreaking approaches that address unmet needs in neurotherapeutics, including immunoassay technologies to support your research. |
|
New product highlights: HTRF™ Phospho-LRRK2 S1292, Total LRRK2 |
| Download white paper |
|
|
Deciphering autoimmune pathways with HTRF assays |
|
| Learn how homogenous HTRF technology is illuminating cell signaling pathways in autoimmune and inflammatory diseases. This literature review provides an in-depth look at biomarkers, signaling cascades, and assay solutions for advancing autoimmune research. |
|
New product highlights: HTRF CCL17 (TARC), CXCL12, Phospho-IRAK4 T345, Phospho-Nucleolin T84, Total Nucleolin, TNFα |
| Get literature review |
|
|
Next-generation cytokines in cancer immunotherapy |
|
| Uncover insights into the evolving role of cytokines in cancer immunotherapy. This blog discusses innovative strategies for enhancing immune responses, with a focus on next-generation cytokine therapeutics shaping the future of oncology. |
|
New product highlight: AlphaLISA™ Biotin Free IL-6, IL-6, CCL17 |
| Read blog |
|
|
Protein Detection Without Worrying About Biotin |
|
| Experience the evolution of AlphaLISA SureFire technology with the new Biotin Free platform. Featuring homogeneous detection of cell-based proteins, this note shows you how to utilize an innovative system optimized for biotin-rich media while maintaining unmatched assay performance and versatility. |
|
New product highlights: AlphaLISA™ SureFire® Biotin Free Phospho/Total ERK1/2, SYK, STAT5, STAT6, AKT1/2/3, STAT3, CDK1, Rb |
| See technical note |
|
